"Market Access Impact: Renal Cell Carcinoma (US)" Published

Market barriers boost net share for 6 major RCC treatments in US. Is your brand one of them?

We researched 9 renal cell carcinoma (RCC) treatments to see what happens to their share of the US market when oncologists can't prescribe freely. The result: 6 of those brands actually saw a net gain.

Is your brand one of them, or one of the 3 that are losing out?

You'll learn how market barriers affect share for 9 major treatments from Bayer/Amgen, BMS, Genentech, Pfizer, and Prometheus.

Plus you'll see which brands your brand is losing share to, which ones you're taking it from, and why-information you can use to compete more effectively.

Reasons to Get this Report

Get Answers to Key Questions about RCC Drug Brands

* Afinitor (everolimus; Novartis): Does Afinitor lose more share to Avastin or Sutent?
* Avastin (bevacizumab; Genentech): Are doctors who don't prescribe either brand more likely to consider Avastin or Opdivo?
* Inlyta (axitinib; Pfizer): Which two barriers contribute equally to Inlyta's small net share loss?
* Nexavar (sorafenib; Bayer/Amgen): Does Nexavar gain more share when other brands are too expensive or when they're not reimbursable?
* Opdivo (nivolumab; BMS): Opdivo and Sutent are prescribed equally. Which one has the clear market share advantage?
* Proleukin (aldesleukin; Prometheus): Which three barriers do more doctors experience with Proleukin than any other brand?
* Sutent (sunitinib; Pfizer): Which two brands would threaten Sutent if market barriers were eliminated?
* Torisel (temsirolimus; Pfizer): Torisel sees a net gain against all but three brands. Which three?
* Votrient (pazopanib; Novartis): Only two market barriers contribute to Votrient's net share gain. What are they?

Full Report Details at
- http://www.fastmr.com/prod/1180416_market_access_impact_renal.aspx?afid=301

Top Takeaways

* Most brands benefit from barriers: Six of the nine surveyed brands saw a net share gain due to barriers. Only three saw a net loss.
* Eliminating barriers would shake up the market: Especially the top of the market, where one middle-ranked brand would move into the top 3, pushing a leading brand out.
* Barrier effect is brand-specific: Each barrier tends to affect one or two brands far more than the others.
* All brands are heavily prescribed: Although a majority of doctors prescribe all but one of the surveyed brands, two brands are more prescribed than any of the others.
* Clear market leaders: Two brands-one of them among the most prescribed-have a clear market share lead.
* Brand perception is good: With a few exceptions, most doctors are willing to consider prescribing the brands they don't currently prescribe.
* Cost barriers have the greatest impact: barriers related to pricing and formulary availability (which is often related) affect more prescriptions than any others.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Market Access Impact: Renal Cell Carcinoma (EU5)
- NPS+ Renal Cell Carcinoma (US)
- Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H1 2015
- NPS+ Renal Cell Carcinoma (EU5)
- Medical Affairs Reputations: Renal Cell Carcinoma (US)